Enhance MD review

A price needs the right unit

Enhance MD markets clinician-directed compounded weight-management programs with ongoing support. The headline price is only useful when attached to the renewal unit and actual inclusions. Its homepage uses monthly language, while its FAQ says subscriptions renew every 28 days. That difference matters for an annual budget: four weeks is not a calendar month. This review assesses the published program, product distinctions and purchase terms. The service may appeal to someone comparing cash-pay care, but the lab-cost conflict and completed-order refund boundary deserve attention before a lower introductory number becomes the basis for choosing it.^{[1] [2]}

For the connected decision, read the related evidence.

The continuing rates and introductory offer

The homepage lists GLP-1 Core semaglutide at $212 and GLP-1 Advanced tirzepatide at $280, with four weeks of medication. It also shows first-order starting promotions of $112 and $180. Those introductory figures should not be carried forward as the continuing bill. The FAQ's 28-day renewal language is the clearer unit for comparing ongoing costs. Confirm the final offer and debit schedule before paying, especially if a discount depends on eligibility or an intake condition. We do not apply an additional advertised promotion ourselves or assume all codes stack. A usable quote identifies both the first charge and what repeats after it.^{[1] [2]}

Lab inclusion is not consistent across the public information

The homepage and product descriptions advertise periodic metabolic lab testing within the program. The public intake disclosure, however, says patients are responsible for laboratory charges and describes a $50 discount to help offset them. That is a material difference for a buyer. We would ask which arrangement applies to the actual order and obtain the answer in writing. Do not assume the subscription is fully inclusive because one landing page says labs are included. A lab order, arranging a test and paying the laboratory are distinct parts of the process. The selected agreement should make the responsibility clear before an initial payment is authorized.^{[1] [3]}

For the connected decision, read our support-model comparison.

The prescription and the platform are separate

The terms describe Enhance MD as the administrative platform, with independent medical groups providing healthcare and pharmacy partners dispensing prescriptions. It is cash-pay service, and eligibility depends on assessment and location. Those distinctions help identify who handles a billing question versus a clinical concern. Ask which clinician is responsible for follow-up, what product would be dispensed and where pharmacy questions go. A broad assertion about availability is less useful than confirming that the actual formulation can be provided in the patient's state. Payment does not guarantee prescribing, and enrollment should not be interpreted as a medication-selection menu.^[4]

Know when a refund stops being available

The FAQ describes pausing or canceling the subscription and an initial refund if the patient is found ineligible. The public intake acknowledgment says completed prescription orders cannot be canceled, refunded or returned. The shipping policy separately says prescription products are not accepted for return. These statements concern different stages, so a cancel-anytime message should not be mistaken for a refund promise on an already completed order. Ask when the next prescription is transmitted and what action must occur before that point to stop the next charge. A future-renewal cancellation should be confirmed rather than inferred from a message about pausing care.^{[2] [3] [5]}

For the connected decision, read our Luvo Health review.

Compounded does not mean approved-equivalent

Enhance MD identifies its weight-management preparations as compounds. FDA does not review a compounded finished product for safety, effectiveness and quality before marketing in the way it reviews an approved drug. A program's scientific language about an ingredient therefore does not establish the same outcome for the dispensed preparation. Ask the clinician why the proposed formulation is appropriate for the patient's medical need and request the exact pharmacy labeling. A branded-drug trial should not become a guarantee for an unstudied combination or formulation. That boundary matters more than a premium name for a program tier.^[6]

Evaluate the support behind the price

Ongoing provider access and a structured assessment can be useful features when symptoms, other medicines or clinical goals change. Their practical quality is not established by the number of features on the homepage. Ask about appointment cadence, response expectations and how a concern reaches the clinician rather than a general support queue. Also ask what happens if treatment is unsuitable after the initial order. A service that explains the process clearly is easier to judge than one relying on a general metabolic-reset promise. Our comparison with other clinician-led programs focuses on continuity and financial clarity rather than assuming a particular outcome from the subscription.

Our verdict

Enhance MD is worth comparing only with the 28-day unit and lab responsibility made explicit. The continuing $212 and $280 figures are more informative than the introductory promotion, but they still require a final product-specific quote. We would resolve the conflicting lab descriptions and the completed-prescription cutoff before payment. If those answers are clear and the clinical model fits, the service may offer a convenient cash-pay pathway. If they remain unclear, a cleaner contract elsewhere can be worth more than a modest price difference. The program should be selected for appropriate care and an understandable obligation, with no assumption of approved-product equivalence or guaranteed weight loss.

Understanding the cost

Continuing semaglutide is listed at $212 and tirzepatide at $280, with the FAQ specifying renewal every 28 days. First-order promotions differ. Public lab-inclusion descriptions conflict with intake lab responsibility; clarify the selected agreement. Completed prescription orders are nonrefundable.